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Abstract This article examines willingness to participate
in future HIV prevention research among gay and bisexual
men in Scotland, UK. Anonymous, self-complete ques-
tionnaires and Orasure
TM
oral fluid samples were collected
in commercial gay venues. 1,320 men were eligible for
inclusion. 78.2% reported willingness to participate in
future HIV prevention research; 64.6% for an HIV vaccine,
57.4% for a behaviour change study, and 53.0% for a rectal
microbicide. In multivariate analysis, for HIV vaccine
research, greater age, minority ethnicity, and not providing
an oral fluid sample were associated with lower willing-
ness; heterosexual orientation and not providing an oral
fluid sample were for microbicides; higher education and
greater HIV treatment optimism were for behaviour
change. STI testing remained associated with being more
willing to participate in microbicide research and frequent
gay scene use remained associated with being more willing
to participate in behaviour change research. Having an STI
in the past 12 months remained significantly associated
with being willing to participate in all three study types.
There were no associations between sexual risk behaviour
and willingness. Although most men expressed willingness
to participate in future research, recruitment of high-risk
men, who have the potential to benefit most, is likely to be
more challenging.
Keywords Men who have sex with men 
HIV prevention  Vaccines  Microbicides 
Behaviour change  Trial participation
Introduction
A resurgence in diagnosed HIV has been noted among men
who have sex with men (MSM) in North America, Western
Europe and Australia [1], and MSM remain the group most
at risk of acquiring HIV in the UK, with estimated preva-
lence of 5% [2]. New HIV prevention strategies are needed
and current policy initiatives set prevention as key to
efforts to combat the epidemic among MSM in the UK
[2, 3].
A recent review of randomized controlled trials (RCTs)
of interventions to reduce the sexual transmission of HIV
infection found only five of 37 had positive effects (all
biomedical—three male circumcision, one STI treatment
and care and one vaccine trial), and only one, non-bio-
medical intervention, targeted MSM [4]. Evidence of the
potential effectiveness of behavioural HIV prevention
interventions for MSM is growing, but few have included
biological endpoints to measure HIV or sexually trans-
mitted infection (STI) acquisition [5]. Although male cir-
cumcision has been shown to reduce the risk of HIV
acquisition among heterosexual men [6], there is not the
same evidence for MSM [7]; a finding recently supported
by our own data [8]. In addition, it appeared unlikely that a
RCT of male circumcision would be viable in this popu-
lation, with only 14% reporting that they would be willing
to participate in a research study on circumcision and HIV
prevention [8]. So far, the Preexposure Prophylaxis Ini-
tiative (iPrEx) Study is the only biomedical intervention
with biological endpoints to have demonstrated efficacy in
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MSM [9]. The lack of effect in most RCTs is argued to be
partly the result of design and implementation problems; an
issue requiring consideration in future studies [4]. Indeed,
assessing the acceptability and feasibility of future pre-
vention efforts prior to initiating interventions is an
important part of their development [10–13].
Since 1996, we have surveyed the HIV-related sexual
behaviour of MSM in Scotland [14–22]. In 2008, we
examined men’s current and potential future contact with
HIV prevention efforts and this article describes the extent
to which MSM were willing to participate in future HIV
prevention research, the factors associated with this, and the
implications for future interventions with this population.
Methods
The 2008 Medical Research Council (MRC) Gay Men’s
Survey collected anonymous, self-complete questionnaires
and (Orasure
TM
) oral fluid specimens. Time and location
sampling was used to recruit a representative sample of
men from commercial gay venues (12 bars and 2 saunas) in
Glasgow and Edinburgh, Scotland’s two largest cities. Bars
were surveyed over a 2-week period in the early (7:00–9:00
p.m.) and late (9:00–11:00 p.m.) evening, and no bar was
visited twice in the same evening. At the end of the 2-week
period, each bar had been visited at both time points on
each day of the week. Saunas were surveyed over two early
evening periods (5:00–7:00 p.m.) and two weekend late
afternoon periods (4:00–6:00 p.m.). Temporary fieldwork-
ers were employed to distribute questionnaires and all men
present or entering the venues were invited to participate.
Of 2,138 men approached, 1,514 men participated in the
survey (70.8% response rate [RR]); 1,508 completed
questionnaires (70.5% RR) and 1,277 provided oral fluid
samples (59.7% RR). 54 (3.6%) heterosexual men who
reported no sexual contact with men in the previous
12 months were excluded from the sample.
The questionnaires included tried and tested measures of
demographics, HIV testing history and sexual risk behav-
iour in the past 12 months used in our surveys since 1996
[14–22]. New questions were pilot tested with the target
population, and amended as necessary, prior to initiating
the survey. The question on willingness to take part in
future research was ‘‘We are looking for new ways to
prevent HIV. Should the following research studies take
place, which would you be willing to take part in?’’, with
participants asked to select ‘yes’, ‘no’ or ‘don’t know’ for
behaviour change programme (e.g. support using con-
doms); using rectal microbicides (e.g. special lube to pre-
vent HIV); HIV vaccine; and circumcision (surgical
removal of foreskin). The four categories were chosen to
reflect prevention methods either available (behaviour
change and circumcision) or under continuing development
(vaccines and microbicides) [4]. Willingness to participate
in circumcision research was particularly low (13.9%), as
has been reported elsewhere [8], and is excluded from the
analyses in this article.
Oral fluid specimens were analysed at the West of
Scotland Specialist Virology Centre (screened for anti-HIV
using an enzyme immunoassay; positives re-screened, and
repeat reactives confirmed using Western Blot). Data were
analysed with SPSS 15.0. Logistic regression was used to
estimate odds ratios and 95% confidence intervals (CI).
Ethical approval was granted by University of Glasgow,
Faculty of Medicine Ethics Committee.
Men with missing data on any of the willingness to
participate variables are excluded from these analyses
(N = 134). In multivariate analysis, when compared to the
1,320 men included in the analyses, men who did not
answer the willingness questions were significantly more
likely to have been surveyed in saunas (12.7% of men who
did not answer the questions vs. 5.5% of men who did,
adjusted odds ratio [AOR] = 2.33, 95% CI 1.24–4.39,
P = 0.009), more likely to be aged 26 years or over
(81.4% vs. 70.5%, AOR = 1.79, 95% CI 1.09–2.95,
P = 0.023), less likely to have further (29.0% vs. 38.6%,
AOR = 0.43, 95% CI 0.24–0.76, P = 0.004) or higher
(40.9% vs. 46.0% AOR = 0.46, 95% CI 0.26–0.78,
P = 0.005) education, more likely to believe that ‘new
drug therapies make people with HIV less infectious’
(33.3% vs. 16.0%, AOR = 1.76, 95% CI 1.02–3.05,
P = 0.042), and were more likely to have not provided an
oral fluid sample (29.1% vs. 14.4%, AOR = 2.13, 95% CI
1.36–3.34, P = 0.001). There were no other significant
differences in sexual health service use, perceived HIV
status, or sexual risk behaviour.
Results
Sample Characteristics
Sample characteristics are shown in Table 1. The majority
of the sample were surveyed in bars and identified as gay.
The median age of participants was 33 years (range
16–73 years); 76.6% lived in the Glasgow or Edinburgh
areas. Only 3.1% reported being from a minority ethnic
group. Approximately half reported degree or post-gradu-
ate education; 47.9% visited the gay scene at least once a
week. Just under half had been tested for HIV or other STIs
in the past 12 months; 3.6% had an HIV-positive oral fluid
sample (4.2% of those who provided samples). Most men
(96.2%) reported some sexual contact in the past
12 months; 26.9% reported 10 or more partners; 12.4%
reported UAI with 2 or more partners; 25.2% reported UAI
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with partners of unknown/discordant HIV status; and 8.6%
had had an STI in the past 12 months.
Willingness to Participate in Future HIV Prevention
Research Studies
A majority (1,032; 78.2%) of men reported willingness to
participate in future HIV prevention research studies, with
most being willing to participate in research for an HIV
vaccine (64.6%); 20.4% were not willing and 15.0% did
not know (Table 2). Again, most men (758; 57.4%)
reported being willing to participate in a behaviour change
study; 26.6% were not and 16.0% did not know. Rectal
microbicide studies were less popular, with 53.0% report-
ing willingness to take part in these; 28.9% were not
willing and 18.2% did not know. Overall, 935 men (70.8%)
reported that they were willing to take part in biomedical
(either vaccine or microbicide) research studies.
Table 1 Sample characteristics (N = 1,320)
n %
Demographics
Survey location
Edinburgh 545 41.3
Glasgow 775 58.7
Survey venue
Bar 1,247 94.5
Sauna 73 5.5
Sexual orientation
Gay 1,187 90.5
Bisexual 108 8.2
Straight 16 1.2
Age
16–25 years 385 29.5
26–35 years 381 29.2
36–45 years 379 29.0
46? years 160 12.3
Area of residence
Glasgow 549 42.7
Edinburgh 436 33.9
Rest of Scotland 208 16.2
Rest of UK 66 5.1
Overseas 28 2.2
Ethnicity
White (UK, Irish or other) 1,276 96.9
Minority ethnic groupa 41 3.1
Qualifications
Secondary (statutory school level) 190 15.4
Further/vocational 475 38.6
Degree/post-graduate 567 46.0
Frequency of gay scene use
Once month or less 323 24.9
2/3 times a month 354 27.3
1/2 times a week 444 34.2
4/5 times a week 178 13.7
HIV treatment optimism 1
Disagree 944 74.6
Agree 321 25.4
HIV treatment optimism 2
Disagree 1,063 84.0
Agree 202 16.0
Sexual health
HIV test in the past 12 months
No 675 52.4
Yes 614 47.6
Other STI test in the past 12 months
No 713 54.5
Yes 595 45.5
Table 1 continued
n %
HIV status (oral fluid specimen result)
HIV-negative 1,080 82.1
HIV-positive 47 3.6
Did not provide oral fluid specimenb 189 14.4
Sexual risk behaviour in the past 12 months
Number of sexual partners
Less than 10 932 73.1
10 or more 343 26.9
Number of anal sex partners
Less than 10 1,126 89.2
10 or more 136 10.8
Number of unprotected anal intercourse (UAI) partners
0/1 partner 1,126 87.6
2 or more partners 160 12.4
UAI with casual partners
No 1,013 78.8
Yes 273 21.2
UAI with partners of unknown/discordant HIV status
No 962 74.8
Yes 324 25.2
STI
No 1,198 91.4
Yes 113 8.6
HIV treatment optimism 1 ‘I am less worried about HIV infection now
that treatments have improved’, HIV treatment optimism 2 ‘I believe
that new drug therapies make people with HIV less infectious’
a Black African, Black Caribbean, Indian, Pakistani, Chinese, Arab,
Latin American & Other/Mixed
b An additional 4 samples were not returned from the laboratory
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Factors Associated with Willingness to Participate
in Future HIV Prevention Research Studies
Table 3 shows the factors associated with willingness to
participate in future HIV prevention studies (‘no’ and
‘don’t know’ responses were combined in these analyses as
the comparison group). The odds of willingness to partic-
ipate in each of the future HIV prevention research studies
were higher among men who had had an HIV or other STI
test, and men who reported having had an STI, in the past
12 months. Willingness to take part in HIV vaccine or
microbicide research was lower among older men and men
who did not provide oral fluid samples. Willingness was
lower for men who resided out with the UK and in men
from minority ethnic groups for vaccine research, and
among straight men for microbicide research. The likeli-
hood of being willing to take part in a behavioural research
study was lower among men with degree or post-graduate
education and among men who agreed with the HIV
treatment optimism statement ‘I am less worried about HIV
infection now that treatments have improved’. It was
higher among men who visited the gay scene once or twice
a week and men reporting 10 or more anal sex partners in
the past 12 months. Among HIV-positive men, 72.3%
reported being willing to take part in a behavioural research
study, compared with 57.9% of HIV-negative men. There
were no differences in the proportions of HIV-positive and
HIV-negative men reporting willingness to participate in
biomedical research, nor between diagnosed and undiag-
nosed HIV-positive men in willingness to participate in any
of the research studies.
Factors significant at the bivariate level were entered
into a multivariate model for each of the HIV prevention
research studies (Table 4). Having an STI in the past
12 months remained significantly associated with being
willing to participate in all three study types. For HIV
vaccine research, greater age, minority ethnicity, and not
providing an oral fluid sample were associated with lower
willingness, while heterosexual orientation and not pro-
viding an oral fluid sample were for microbicide research.
Higher education level and greater HIV treatment opti-
mism were associated with not being willing to take part in
behaviour change research. STI testing remained associ-
ated with being more willing to participate in microbicide
research and frequency of gay scene use remained associ-
ated with being more willing to participate in behaviour
change research.
Discussion
This is the first study to assess future willingness to par-
ticipate in prevention research studies among community-
based surveys of gay and bisexual men in Scotland. First,
there are some limitations to note when considering these
results. This was a bar and sauna sample so only men who
visit the venues surveyed have the opportunity to partici-
pate, and our findings should be interpreted within this
context. Willingness to participate in prevention research
could be different among men who did not answer these
questions and in the wider population of gay men who do
not frequent the commercial gay scene. Participants were
only asked if they would be willing to participate in future
research studies, not why this may or may not be the case.
As the question was hypothetical, we cannot assume that
willingness would equal actual participation. No descrip-
tion of what could be involved in taking part in such
research was provided. However, the results provide
interesting insight into men’s willingness to participate in
such studies and this is important for planning future
interventions and HIV prevention efforts.
Just over three quarters of the men surveyed reported
that they were willing to participate in future HIV pre-
vention research studies, with greater willingness to par-
ticipate in biomedical than behavioural studies. It is
particularly interesting to note that willingness to partici-
pate in these studies was considerably higher than the level
of willingness to participate in male circumcision research
in this population [8]. The former have to date, for the most
part, not shown a positive effect on reducing HIV trans-
mission [4], while the latter is the biomedical intervention
with, arguably, the greatest effect on (albeit hetero) sexual
transmission [4]. This raises the query of whether men are
aware of male circumcision as HIV prevention, and its
limited potential as an intervention for MSM [7], or whe-
ther there is some other reason that such an intervention is
unattractive to them. It is also interesting to note that
willingness to participate in biomedical research was lower
among men who did not provide oral fluid samples to be
tested for HIV. When men who did and did not provide oral
specimens were compared only age was significantly dif-
ferent, with men aged 26 ? years less likely to provide
samples [8]. It is possible that men who did not provide
Table 2 Willingness to participate in future HIV prevention research
studies (N = 1,320)
Willingness to participate
Yes No Don’t know
n % n % n %
HIV vaccine 853 64.6 269 20.4 198 15.0
Behaviour change
programme
758 57.4 351 26.6 211 16.0
Using rectal
microbicides
699 53.0 381 28.9 240 18.2
AIDS Behav (2012) 16:1420–1429 1423
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samples have concerns about participating in any kind of
biomedical research.
A review of (mainly North American) HIV vaccine
preparedness studies found willingness to participate in
vaccine trials ranged from 23% to 94% among MSM [23].
Here, almost two-thirds of men expressed willingness to
participate in HIV vaccine research studies. This is con-
siderably higher than the proportion reported in the only
other UK study of this topic among MSM; 23% reported
likelihood of participating in an HIV vaccine trial in a
London gym-based survey of MSM [24]. It is possible that
men see these as having the greatest potential benefits to
themselves and their community, and both personal and
altruistic reasons have been identified as motives for par-
ticipating in previous trials [25]. However, a US study of
MSM’s knowledge and acceptability of biomedical inter-
ventions found vaccines were the most commonly known
intervention types [26], so it could be that men are simply
more likely to have heard of these. Half of the men sur-
veyed said that they were willing to participate in a rectal
microbicide research study. This compares to a previous
American study, in which around two-thirds of gay men
reported they would be willing to participate in microbi-
cide trials [27].
Although one vaccine trial has reported (limited) posi-
tive results [28], it is unlikely that a vaccine will become
available in the immediate future, with considerable further
research required [28, 29]. So far, all of the microbicide
candidates are for vaginal rather than rectal use [4], and
few acceptability research studies have been conducted
among MSM [30]. If HIV vaccine and rectal microbicide
trials were to be initiated with MSM in the UK, further
research would be required to assess the factors that could
facilitate or prevent participation in this population. Edu-
cation and community mobilisation could increase will-
ingness to participate in such studies [31], and
consideration should be given to describing trial protocols
to potential participants as part of assessing willingness to
join research projects.
There is continuing interest in the potential for behav-
ioural interventions among MSM in Scotland [3], and over
half of the men surveyed indicated willingness to partici-
pate in this type of research. However, men who were
treatment optimistic, and less worried about HIV now
treatments had improved, were less likely to be willing to
do so. Although only a minority of MSM are optimistic
(see Table 1 and as noted elsewhere [32, 33]), associations
between treatment optimism and sexual risk behaviour
have been recognised [32–34]. Increases in sexual risk
behaviour cannot be fully accounted for by increasing
treatment optimism [35–37], but this issue nevertheless
remains a challenge and something to consider during
recruitment for a behaviour change research study.T
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Table 4 Factors associated with willingness to take part in future HIV prevention research studies: multivariate logistic regression (N = 1,320)
Willing to take part in HIV
vaccine study
Willing to take part in rectal
microbicide study
Willing to take part in HIV prevention
behaviour change study
AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value
Sexual orientation
Gay 1
Bisexual 0.82 0.55–1.23 0.334
Straight 0.22 0.06–0.79 0.020
Age
16–25 years 1 1
26? years 0.69 0.53–0.90 0.007 0.78 0.61–1.00 0.052
Area of residence
Glasgow 1
Edinburgh 0.95 0.72–1.24 0.680
Rest of Scotland 0.95 0.67–1.34 0.759
Rest of UK 1.03 0.59–1.78 0.925
Overseas 0.55 0.25–1.20 0.132
Ethnicity
White (UK, Irish or other) 1
Minority ethnic groupa 0.39 0.20–0.74 0.004
Qualifications
Secondary (statutory school level) 1
Further/vocational 0.73 0.51–1.04 0.080
Degree/post-graduate 0.64 0.45–0.91 0.013
Frequency of gay scene use
Once month or less 1
2/3 times a month 0.95 0.70–1.29 0.737
1/2 times a week 1.45 1.07–1.95 0.016
4/5 times a week 1.13 0.77–1.66 0.536
HIV treatment optimism 1
Disagree 1
Agree 0.75 0.57–0.97 0.030
HIV test in the past 12 months
No 1 1 1
Yes 1.09 0.78–1.52 0.609 1.02 0.74–1.39 0.915 1.30 0.95–1.80 0.105
Other STI test in the past 12 months
No 1 1 1
Yes 1.29 0.92–1.80 0.138 1.46 1.06–2.01 0.020 0.98 0.71–1.36 0.911
HIV status (oral fluid specimen result)
HIV-negative 1 1
HIV-positive 1.04 0.54–2.00 0.912 1.09 0.59–2.02 0.775
Did not provide oral fluid specimen 0.62 0.45–0.86 0.004 0.70 0.51–0.96 0.029
Number of anal intercourse partners in past 12 months
Less than 10 1
10 or more 1.27 0.85–1.88 0.239
STI in past 12 months
No 1 1 1
Yes 1.85 1.14–3.03 0.014 1.82 1.18–2.82 0.007 2.22 1.39–3.53 0.001
OR odds ratio, 95% CI 95% confidence interval, HIV treatment optimism 1 ‘I am less worried about HIV infection now that treatments have improved’
a Black African, Black Caribbean, Indian, Pakistani, Chinese, Arab, Latin American & Other/Mixed
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Future willingness to participate in vaccine, microbicide
or behaviour change research studies was greater among
service users, particularly among men who reported having
had an STI in the past 12 months. This suggests existing
services may be appropriate venues within which to recruit
men for future research. Intervention delivery in these
settings has previously been identified as a characteristic of
successful interventions among people living with HIV
[38], though a wider range of recruitment settings may be
necessary to recruit sufficient numbers, and relevant risk
groups, of MSM [39]. Willingness to participate in
behaviour change was also higher among HIV-positive
men, a group for whom, to date, behavioural interventions
have proven largely ineffective [38].
Previous research found men at higher risk of HIV were
more likely to be willing to take part in HIV vaccine trials
[23]. Here, the lack of association between sexual risk
behaviours (other than having had an STI in the past
12 months) and such willingness suggests it may be diffi-
cult to recruit adequate numbers of men at higher risk of
HIV (particularly beyond the clinical setting); a finding that
has implications for the design (and cost) of such future
research. Sherr et al. estimated that a minimum of 15,000
HIV-negative men would need to be approached to recruit
1,000 high-risk HIV-negative men into a vaccine trial
(based on a willingness to participate rate of 6.9%) [24].
Our study identified 189 men (12.5% of the total survey
sample) who tested HIV-negative, reported UAI with
partners of unknown or discordant HIV status in the past
12 months and were willing to participate in an HIV vac-
cine research study. With a 70.5% survey RR, over 10,000
men would have to be approached to achieve a sample
size of 8,000 men in order to recruit 1,000 such high-risk
HIV-negative men into a trial.
To be adequately powered to show effect on HIV inci-
dence, trials require large sample sizes. A definitive phase
III trial with 95% power to detect an effect with a 60%
effective vaccine would require approximately 6,000 par-
ticipants from a population with annual 2% HIV incidence
[40]. Based on the figures noted above, 60,000 men would
have to be approached to achieve this sample size, requiring
large multi-centre (and even multi-country) studies.
Combination prevention, which incorporates biomedical
and behavioural, as well as social and structural, interven-
tions has been argued as the way forward for HIV preven-
tion [41]. The detailed assessment of the acceptability and
feasibility of such interventions is vital [10–13], particularly
to avoid the flaws that can lead to ‘flat’ results [4]. Our
findings suggest recruitment of high-risk men, who have the
potential to benefit most from such interventions, is likely to
be challenging, time consuming, and hence costly. The best
means of facilitating this should be examined through fea-
sibility studies, prior to initiating intervention trials.
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